These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 34167433)

  • 1. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?
    Rizzo A; Dadduzio V; Ricci AD; Massari F; Di Federico A; Gadaleta-Caldarola G; Brandi G
    Expert Opin Investig Drugs; 2022 Apr; 31(4):371-378. PubMed ID: 34167433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
    Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
    Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular therapies for HCC: Looking outside the box.
    Faivre S; Rimassa L; Finn RS
    J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
    Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
    BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
    Ikeda M; Kobayashi M; Tahara M; Kaneko S
    Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
    Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
    Perera S; Kelly D; O'Kane GM
    Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.
    Wang Y; Jiang M; Zhu J; Qu J; Qin K; Zhao D; Wang L; Dong L; Zhang X
    Biomed Pharmacother; 2020 Dec; 132():110797. PubMed ID: 33068935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma.
    Wu CJ; Lee PC; Hung YW; Lee CJ; Chi CT; Lee IC; Hou MC; Huang YH
    Cancer Immunol Immunother; 2022 Nov; 71(11):2631-2643. PubMed ID: 35347395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report.
    Liu Z; Li X; He X; Xu Y; Wang X
    BMC Cancer; 2019 Nov; 19(1):1062. PubMed ID: 31703571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
    Bangaru S; Marrero JA; Singal AG
    Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review.
    Mo DC; Luo PH; Huang SX; Wang HL; Huang JF
    Int Immunopharmacol; 2021 Feb; 91():107281. PubMed ID: 33338862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral chemotherapy for the treatment of hepatocellular carcinoma.
    Yamamoto S; Kondo S
    Expert Opin Pharmacother; 2018 Jun; 19(9):993-1001. PubMed ID: 29913090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
    Oikonomopoulos G; Aravind P; Sarker D
    Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
    Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
    Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison.
    Casadei-Gardini A; Tada T; Shimose S; Kumada T; Niizeki T; Cascinu S; Cucchetti A
    Target Oncol; 2021 Mar; 16(2):249-254. PubMed ID: 33638735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma.
    Ged Y; Lee CH
    Expert Rev Anticancer Ther; 2022 Oct; 22(10):1049-1059. PubMed ID: 36154355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
    Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
    Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy.
    Zhao Y; Zhang YN; Wang KT; Chen L
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188391. PubMed ID: 32659252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.